NO20053530D0 - Multivalente lymfotoksin-beta-reseptorantagonister samt anvendelse derav - Google Patents
Multivalente lymfotoksin-beta-reseptorantagonister samt anvendelse deravInfo
- Publication number
- NO20053530D0 NO20053530D0 NO20053530A NO20053530A NO20053530D0 NO 20053530 D0 NO20053530 D0 NO 20053530D0 NO 20053530 A NO20053530 A NO 20053530A NO 20053530 A NO20053530 A NO 20053530A NO 20053530 D0 NO20053530 D0 NO 20053530D0
- Authority
- NO
- Norway
- Prior art keywords
- lymphotoxin
- multivalent
- receptor antagonists
- beta receptor
- beta
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43515402P | 2002-12-20 | 2002-12-20 | |
PCT/US2003/041393 WO2004058191A2 (en) | 2002-12-20 | 2003-12-22 | Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20053530D0 true NO20053530D0 (no) | 2005-07-19 |
NO20053530L NO20053530L (no) | 2005-09-20 |
Family
ID=32682169
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20053530A NO20053530L (no) | 2002-12-20 | 2005-07-19 | Multivalente lymfotoksin-beta-reseptorantagonister samt anvendelse derav |
Country Status (8)
Country | Link |
---|---|
US (1) | US20060104971A1 (no) |
EP (1) | EP1583503A4 (no) |
JP (1) | JP2006515750A (no) |
CN (1) | CN100473664C (no) |
AU (1) | AU2003299984A1 (no) |
CA (1) | CA2511013A1 (no) |
NO (1) | NO20053530L (no) |
WO (1) | WO2004058191A2 (no) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6312691B1 (en) * | 1996-01-26 | 2001-11-06 | Jeffrey L. Browning | Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents |
US5925351A (en) | 1995-07-21 | 1999-07-20 | Biogen, Inc. | Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease |
YU28503A (sh) * | 2000-10-13 | 2006-05-25 | Biogen Inc. | Humanizovana anti-lt-beta-r antitela |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
AU2003256299A1 (en) * | 2002-07-01 | 2004-01-19 | Human Genome Sciences, Inc. | Antibodies that specifically bind to reg iv |
AU2003248782A1 (en) * | 2002-07-01 | 2004-01-19 | Biogen Idec Ma Inc. | Humanized anti-lymphotoxin beta receptor antibodies |
KR20050094819A (ko) * | 2002-12-20 | 2005-09-28 | 바이오겐 아이덱 엠에이 인코포레이티드 | 화학요법제와 조합된 림프독소 베타 수용체 약제 |
EP1641826A2 (en) * | 2003-06-27 | 2006-04-05 | Biogen Idec MA Inc. | Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions |
CN1980957A (zh) | 2004-03-23 | 2007-06-13 | 比奥根艾迪克Ma公司 | 受体偶联剂及其治疗用途 |
WO2006074399A2 (en) | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
NI200800032A (es) | 2005-07-25 | 2009-03-23 | Reducción de célula b utilizando moléculas de unión específicas cd37 y cd20 | |
BRPI0709598A8 (pt) * | 2006-03-17 | 2019-01-08 | Biogen Idec Inc | composições de polipeptídeos estabilizados |
AU2016231617B2 (en) * | 2006-06-12 | 2018-08-23 | Aptevo Research And Development Llc | Single-chain multivalent binding proteins with effector function |
AU2014200661B2 (en) * | 2006-06-12 | 2016-06-30 | Aptevo Research And Development Llc | Single-chain multivalent binding proteins with effector function |
MX2008015524A (es) * | 2006-06-12 | 2009-01-13 | Trubion Pharmaceuticals Inc | Proteinas de union multivalentes monocatenarias con funcion efectora. |
KR20090083958A (ko) * | 2006-10-20 | 2009-08-04 | 바이오겐 아이덱 엠에이 인코포레이티드 | 가용성 림프독소-베타-수용체를 이용한 탈수초성 장애의 치료 |
US8338376B2 (en) * | 2006-10-20 | 2012-12-25 | Biogen Idec Ma Inc. | Compositions comprising variant LT-B-R-IG fusion proteins |
BRPI0814060A2 (pt) * | 2007-07-06 | 2015-01-06 | Trubion Pharmaceuticals Inc | Peptídeos ligantes tendo um domínio de ligação específico disposto em c-terminal |
WO2009018386A1 (en) * | 2007-07-31 | 2009-02-05 | Medimmune, Llc | Multispecific epitope binding proteins and uses thereof |
KR100967623B1 (ko) * | 2008-02-22 | 2010-07-05 | 전남대학교산학협력단 | 림포톡신을 포함하는 자궁경부암 예방 또는 치료용 조성물 |
SI2132228T1 (sl) | 2008-04-11 | 2011-10-28 | Emergent Product Dev Seatle | CD37 imunoterapevtik in kombinacija z njegovim bifunkcionalnim kemoterapevtikom |
EP2844290A4 (en) * | 2012-05-01 | 2015-12-16 | Glaxosmithkline Llc | NOVEL ANTIBODIES |
CA2904260C (en) * | 2013-02-04 | 2021-10-19 | University Of Huddersfield | Composition comprising a tnfr agonist and at least one thioredoxin inhibitor for use in the treatment of carcinoma. |
TWI700295B (zh) | 2013-12-16 | 2020-08-01 | 馬來西亞商Mab探索私人有限公司 | 對會感染人類之腸病毒具有專一性之抗體 |
MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
WO2017053469A2 (en) | 2015-09-21 | 2017-03-30 | Aptevo Research And Development Llc | Cd3 binding polypeptides |
AU2016336451B2 (en) | 2015-10-06 | 2023-06-29 | Regents Of The University Of Minnesota | Therapeutic compounds and methods |
JP2024508207A (ja) | 2020-12-02 | 2024-02-26 | ブイアイビー ブイゼットダブリュ | がんに対する組み合わせ治療におけるltbrアゴニスト |
WO2022117569A1 (en) | 2020-12-02 | 2022-06-09 | Oncurious Nv | A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer |
WO2023198848A1 (en) | 2022-04-13 | 2023-10-19 | Vib Vzw | An ltbr agonist in combination therapy against cancer |
WO2023218320A1 (en) * | 2022-05-11 | 2023-11-16 | Pfizer Inc. | Anti-lymphotoxin beta receptor antibodies and methods of use thereof |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US669941A (en) * | 1898-12-17 | 1901-03-12 | Electric Axle Light & Power Company | Electric switch. |
US5618920A (en) * | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
ATE397665T1 (de) * | 1992-12-04 | 2008-06-15 | Biogen Idec Inc | Lymphotoxin-beta, lymphotoxin-beta komplexe, pharmazeutische zubereitungen und therapeutische verwendungen davon |
US6312691B1 (en) * | 1996-01-26 | 2001-11-06 | Jeffrey L. Browning | Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents |
CN1146442C (zh) * | 1995-01-26 | 2004-04-21 | 拜奥根有限公司 | 作为抗肿瘤剂的淋巴毒素-α/β复合体和抗淋巴毒素-β受体抗体 |
US5925351A (en) * | 1995-07-21 | 1999-07-20 | Biogen, Inc. | Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease |
US7060667B1 (en) * | 1998-01-30 | 2006-06-13 | Biogen Idec Ma, Inc. | Treatment of follicular lymphomas using inhibitors of the LT pathway |
TR200504220T2 (tr) * | 1998-12-17 | 2007-04-24 | Biogen Idec Ma Inc. | Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem. |
SI2857516T1 (sl) * | 2000-04-11 | 2017-09-29 | Genentech, Inc. | Multivalentna protitelesa in njihove uporabe |
AU2001279678B2 (en) * | 2000-06-30 | 2005-08-18 | Innogenetics N.V. | Differential diagnosis of neurological diseases |
AU8678501A (en) * | 2000-08-24 | 2002-03-04 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor |
YU28503A (sh) * | 2000-10-13 | 2006-05-25 | Biogen Inc. | Humanizovana anti-lt-beta-r antitela |
US20030133939A1 (en) * | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US7576185B2 (en) * | 2002-03-05 | 2009-08-18 | Genentech, Inc. | PRO34128 antibodies |
AU2003248782A1 (en) * | 2002-07-01 | 2004-01-19 | Biogen Idec Ma Inc. | Humanized anti-lymphotoxin beta receptor antibodies |
KR20050094819A (ko) * | 2002-12-20 | 2005-09-28 | 바이오겐 아이덱 엠에이 인코포레이티드 | 화학요법제와 조합된 림프독소 베타 수용체 약제 |
-
2003
- 2003-12-22 WO PCT/US2003/041393 patent/WO2004058191A2/en active Search and Examination
- 2003-12-22 JP JP2004562588A patent/JP2006515750A/ja active Pending
- 2003-12-22 AU AU2003299984A patent/AU2003299984A1/en not_active Abandoned
- 2003-12-22 CN CNB2003801090429A patent/CN100473664C/zh not_active Expired - Fee Related
- 2003-12-22 EP EP03800249A patent/EP1583503A4/en not_active Withdrawn
- 2003-12-22 CA CA002511013A patent/CA2511013A1/en not_active Abandoned
-
2005
- 2005-06-17 US US11/155,444 patent/US20060104971A1/en not_active Abandoned
- 2005-07-19 NO NO20053530A patent/NO20053530L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2004058191A3 (en) | 2005-12-29 |
EP1583503A4 (en) | 2006-08-09 |
CN1798765A (zh) | 2006-07-05 |
CA2511013A1 (en) | 2004-07-15 |
WO2004058191A2 (en) | 2004-07-15 |
EP1583503A2 (en) | 2005-10-12 |
CN100473664C (zh) | 2009-04-01 |
US20060104971A1 (en) | 2006-05-18 |
JP2006515750A (ja) | 2006-06-08 |
AU2003299984A1 (en) | 2004-07-22 |
NO20053530L (no) | 2005-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20053530D0 (no) | Multivalente lymfotoksin-beta-reseptorantagonister samt anvendelse derav | |
IS8190A (is) | Ný P2X7 viðtakamótlyf og notkun þeirra | |
IS7329A (is) | Flúr setinn sýklóalkanóindól og notkun þeirra semprostaglandín D2 viðtaka mótlyfja | |
NO20051871D0 (no) | Opioid reseptorantagonister | |
CY2015029I2 (el) | Τρικυκλικοι ανταγωνιστες υποδοχεα θρομβινης | |
DK1345920T3 (da) | Hidtil ukendte sulfamider og anvendelse deraf som endothelinreceptorantagonister | |
NO20053529D0 (no) | Lymfotoksin-beta-reseptormedikamenter i kombinasjon med kjemoterapeutiske midler | |
NO20032277L (no) | Aminotiazoler og deres anvendelse som adenosinreseptorantagonister | |
ATE413400T1 (de) | Cgrp-rezeptorantagonisten | |
ID30401A (id) | Turunan-turunan indol dan penggunaannya sebagai antagonis mcp-1 | |
DK1682142T3 (da) | M3-muscarin-acetylcholin-receptor-antagonister | |
HK1087703A1 (en) | Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists | |
NO20030471D0 (no) | Karboksamidforbindelser og deres anvendelse som antagonister for en 11CBY-reseptor | |
ATE394375T1 (de) | Zusammensetzung enthaltend einen tachykininrezeptor antagonisten und einen serotonin-wiederaufnahmehemmer | |
IS8526A (is) | CRF viðtakamótlyf og aðferðir tengdar þeim | |
IS8315A (is) | Breytt IL-4 mútein viðtaka mótlyf | |
DE60114413D1 (de) | Substituierte 1-aminoalkyl-lactame und deren verwendung als muscarinrezeptor-antagonisten | |
EE200200667A (et) | Bitsüklilised tsükloheksüülamiinid ja nende kasutamine NMDA retseptori antagonistidena | |
HK1087924A1 (en) | Substituted 1-piperidin-3-yl-4-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists | |
NO20043799L (no) | 2-oksasolaminer og deres anvendelse som 5-HT2B reseptor antagonister | |
PT1448566E (pt) | Antagonistas do receptor quimioquina e metodos de utilizacao do mesmo | |
SE0200401L (sv) | Strömriktare samt användning därav | |
FI20031456A0 (fi) | Selektiivisiä somatostatiinireseptori 1 ja/tai 4 -agonisteja ja -antagonisteja | |
NO20024328L (no) | Ístrogen-regulert G-protein gamma-subenhet: sammensetninger samt anvendelse derav | |
SE0003995D0 (sv) | Receptoragonister och antagonister |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |